- Home
- AARD vs ANIK Comparison
AARD vs ANIK Comparison
Compare AARD & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- ANIK
- Stock Information
- Founded
- AARD 2017
- ANIK 1983
- Country
- AARD United States
- ANIK United States
- Employees
- AARD N/A
- ANIK N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- ANIK Medical/Dental Instruments
- Sector
- AARD Health Care
- ANIK Health Care
- Exchange
- AARD Nasdaq
- ANIK Nasdaq
- Market Cap
- AARD 216.6M
- ANIK 243.4M
- IPO Year
- AARD 2025
- ANIK 1993
- Fundamental
- Price
- AARD $7.74
- ANIK $15.30
- Analyst Decision
- AARD Strong Buy
- ANIK Buy
- Analyst Count
- AARD 4
- ANIK 2
- Target Price
- AARD $31.50
- ANIK $22.00
- AVG Volume (30 Days)
- AARD 113.5K
- ANIK 89.0K
- Earning Date
- AARD 01-01-0001
- ANIK 03-12-2025
- Dividend Yield
- AARD N/A
- ANIK N/A
- EPS Growth
- AARD N/A
- ANIK N/A
- EPS
- AARD N/A
- ANIK N/A
- Revenue
- AARD N/A
- ANIK $119,907,000.00
- Revenue This Year
- AARD N/A
- ANIK N/A
- Revenue Next Year
- AARD N/A
- ANIK $8.50
- P/E Ratio
- AARD N/A
- ANIK N/A
- Revenue Growth
- AARD N/A
- ANIK N/A
- 52 Week Low
- AARD $7.74
- ANIK $14.95
- 52 Week High
- AARD $19.58
- ANIK $29.12
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- ANIK 39.25
- Support Level
- AARD N/A
- ANIK $15.02
- Resistance Level
- AARD N/A
- ANIK $15.62
- Average True Range (ATR)
- AARD 0.00
- ANIK 0.68
- MACD
- AARD 0.00
- ANIK -0.08
- Stochastic Oscillator
- AARD 0.00
- ANIK 25.11
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.